The myeloperoxidase (MPO) monoclonal antibody market is a rapidly expanding niche within the broader biopharmaceutical landscape, offering powerful tools for the diagnosis, research, and treatment of a range of inflammatory and malignant diseases. The myeloperoxidase monoclonal antibody market is experiencing explosive growth, driven by the rising prevalence of chronic inflammatory and autoimmune conditions, technological advancements in antibody engineering, and a growing demand for precision medicine. Valued at USD 1.16 billion in 2024, the market is projected to reach USD 4.5 billion by 2032, at a staggering CAGR of 18.41%. This growth underscores the critical and expanding utility of MPO-targeting antibodies in modern healthcare.

Myeloperoxidase is an enzyme released by activated neutrophils and macrophages, playing a key role in the body's immune response but also implicated in the pathology of numerous diseases when dysregulated. MPO monoclonal antibodies are highly specific tools used to detect, measure, and neutralize this enzyme. The market is segmented by disease indication, with inflammatory diseases currently holding a significant share, driven by the need for better management of conditions like rheumatoid arthritis and vasculitis. However, the cancer segment is expected to see substantial growth as research uncovers MPO's role in tumor progression and immune evasion. The market includes antibodies for research, diagnostic, and therapeutic applications.

Key drivers of this market include the increasing prevalence of chronic diseases and growing awareness of MPO's role in disease. Technological advancements in antibody development are also a major factor. For a comprehensive understanding of these dynamics, exploring the myeloperoxidase monoclonal antibody market provides essential insights.